Market Overview

UPDATE: Goldman Sachs Reiterates Sell Rating, Raises PT on Eli Lilly & Co.

Share:
Related LLY
Analyst: Here's Why Eli Lilly Is Worth More Than It Used To Be
SunTrust Names Eli Lilly, Merck, Bristol-Myers as 'Favorite' Pharma Firms
European Ad Comm recommends approval of combo pill for type 2 diabetes (Seeking Alpha)

In a report published Friday, Goldman Sachs Group reiterated its Sell rating on Eli Lilly & Co. (NYSE: LLY), and raised its price target from $39.00 to $42.00.

Goldman Sachs noted, “We reiterate our Sell rating on LLY shares (relative to our Attractive coverage view on Pharma) and would take profits on recent strength driven by what we believe is a solanezumab hope-induced trade, which we see as premature. Based on our analysis, LLY shares already reflect $7 bn in Sola optionality value and a 50% probability of sola success, driven by the hint of efficacy seen in a pooled analysis of both studies in secondary endpoints. Data at ANA on Oct 8 will be a key to either supporting or significantly challenging that view. We are skeptical about a meaningful benefit and at the very best, expect that LLY will have to run another confirmatory Phase 3 clinical trial for 18 months in mild patients if the efficacy signal is based on a meaningful clinical benefit. This pushes the timeline out by 3-4 years.”

Eli Lilly & Co. closed on Thursday at $47.15.

Latest Ratings for LLY

DateFirmActionFromTo
Mar 2015SunTrust Robinson HumphreyMaintainsBuy
Mar 2015Leerink SwannMaintainsOutperform
Feb 2015JefferiesMaintainsBuy

View More Analyst Ratings for LLY
View the Latest Analyst Ratings

Posted-In: Goldman Sachs GroupAnalyst Color Price Target Analyst Ratings

 

Related Articles (LLY)

Around the Web, We're Loving...